Insights Into Multiple Myeloma (MM)

Perspectives on current treatment practices regarding frontline therapy of MM, the evolving role of MRD testing in MM, treatment in later lines of therapy, and attitudes toward recently introduced agents

Central #1 – March 24, 2022

Faculty Chair

Krina Patel, MD

MD Anderson Cancer Center

Puerto Rico – June 25, 2022

Faculty Chair

Ariel F. Grajales-Cruz, MD

Moffitt Cancer Center

Northeast #1 – August 20, 2022

Faculty Chair

Sagar Lonial, MD

Winship Cancer Institute, Emory University

Southwest – TBC, 2022

Faculty Chair

TBC

TBC

Southeast – November 16, 2022

Faculty Chair

Jonathan Kaufman

Winship Cancer Institute

Northwest – November 19, 2022

Faculty Chair

Jeffrey Matous, MD

Colorado Blood Cancer Institute

Northeast #2 – November 10, 2022

Faculty Chair

Ajai Chari, MD

Mount Sinai

West – December 14, 2022

Faculty Chair

Peter Forsberg, MD

UCHealth

Central #2 – December 15, 2022

Faculty Chair

Morie Gertz, MD

Mayo Clinic

More Information

  • Virtual series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual series
  • Puerto Rico

More Information

  • Philadelphia, PA
  • Delaware, Massachusetts, New Jersey, New York, and Pennsylvania

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

More Information

  • Virtual series
  • Delaware, Massachusetts, New Jersey, New York, and Pennsylvania

More Information

  • Virtual series
  • West

More Information

  • Virtual series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of MM
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies are obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.